Enanta Pharmaceuticals (ENTA)
(Real Time Quote from BATS)
$11.06 USD
-0.22 (-1.95%)
Updated Sep 23, 2024 03:46 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ENTA 11.06 -0.22(-1.95%)
Will ENTA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTA
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
ENTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Other News for ENTA
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Buy Rating Affirmed on Enanta Pharmaceuticals’ Promising Drug Pipeline and Strategic Expansion into Immunology
Oppenheimer Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution